GHRP-2 vs GHRP-6: Selectivity and Receptor Data

What Are Growth Hormone Releasing Peptides?

Growth hormone releasing peptides (GHRPs) are a class of small synthetic peptides that mimic ghrelin, the body's “hunger hormone,” at the growth hormone secretagogue receptor (GHS-R) in the pituitary gland and hypothalamus. By activating this receptor, they prompt the anterior pituitary somatotrophs to release a pulse of the body's own growth hormone, which subsequentlyinfluences systemic insulin-like growth factor 1 (IGF-1) levels, rather than introducing synthetic GH from outside.

That distinction matters: GHRPs work upstream, encouraging endogenous, pulsatile GH release that preserves the body's feedback loops, whereas injecting recombinant HGH supplies the hormone directly and overrides them. GHRP-2 and GHRP-6 are two of the most studied members of this family.

Core Mechanism and Pituitary Response

When a GHRP binds the GHS-R1a, it stimulates GH release; somatostatin, the hormone that normally brakes GH, blocks this response (Bowers et al. 1984). Because they mimic ghrelin, GHRPs can additionally influence appetite and, at higher doses, modestly raise cortisol and prolactin. The degree of each effect is what separates the individual peptides.

The GHRP-6 Profile

GHRP-6 is the classic appetite-stimulating GHRP and synthetic hexapeptide, often compared to hexarelin in potency studies. Its ghrelin-like signaling is associated with increased hunger, which matters in research on food intake and is a confound in other designs. Its GH-releasing potency is solid but generally considered lower than GHRP-2 at comparable doses.

How GHRP-6 led to the receptor and to ghrelin

GHRP-6 came before its receptor was known. Bowers and colleagues described it in 1984 as a synthetic hexapeptide that released growth hormone from pituitary tissue and in rats, monkeys, lambs and calves without releasing LH, FSH, TSH or prolactin, and they found that somatostatin blocked the effect (Bowers et al. 1984). The first human study followed in 1989: in healthy men, growth hormone rose sharply and in proportion to the amount, while LH, FSH, TSH and ACTH stayed unchanged (Ilson et al. 1989).

For twelve years the peptide had a known effect and an unknown target. The receptor was cloned in 1996, a G protein-coupled receptor in pig and human pituitary and hypothalamus that Howard and colleagues showed to be the target of the growth hormone secretagogues; they read its existence as support for an undiscovered natural hormone (Howard et al. 1996). Bowers made the same argument in a 1998 review, describing the peptides as acting on both the hypothalamus and the pituitary and as reflecting a natural hormone yet to be isolated (Bowers 1998). The natural ligand was found in the stomach. In 1999 Kojima and colleagues purified ghrelin from rat stomach, a 28-residue peptide whose activity requires an n-octanoyl group on serine 3 (Kojima et al. 1999). The finding that ghrelin also stimulates food intake in rats (Wren et al. 2000) is the basis for the appetite effects later attributed to the synthetic peptides.

The GHRP-2 Profile

GHRP-2 is regarded as a more potent GH releaser with comparatively less appetite stimulation than GHRP-6 — though it is not appetite-free. It can also nudge ACTH, cortisol, and prolactin upward at higher doses. For research focused on the GH pulse without large changes in food intake, GHRP-2 is typically the more relevant choice.

Pralmorelin as a diagnostic agent, and its pharmacokinetics in children

Under the name pralmorelin (development codes include KP-102 and GPA 748), GHRP-2 was developed as a diagnostic agent for growth hormone deficiency (Ref 2004). The rationale was its ability to raise plasma growth hormone markedly in healthy subjects regardless of sex, obesity or age, while the rise in growth hormone deficiency is significantly lower (Ref 2004). A receiver-operating-characteristic analysis put the cut-off at a growth hormone peak of 15.0 µg/L for separating deficient from normal secretion, and Kaken acquired worldwide manufacturing and marketing rights (Ref 2004). A 2010 analytical paper described GHRP-2 as in use for diagnosing growth hormone deficiency. Because growth hormone secretagogues are prohibited by the World Anti-Doping Agency, the same paper set out a urine test for the intact peptide and for its metabolite D-Ala-D-2-Nal-Ala-OH, the first three residues of the chain (Okano et al. 2010).

The pharmacokinetics have been measured in children. In a phase I study of ten prepubertal children with short stature, plasma GHRP-2 declined in two phases, with a terminal half-life of 0.55 hours, and growth hormone measured alongside it was modelled as the response (Pihoker et al. 1998). These figures come from a single exposure in a small paediatric group, so they describe how quickly the peptide clears rather than any longer-term pattern.

GHRP-2 vs GHRP-6: Head-to-Head

Neither is strictly “better” — they answer different research questions. If unwanted hunger is a problem, GHRP-2 is usually preferred; if increased intake is part of the design, GHRP-6 fits.

The Power of Synergy: GHRPs with a GHRH Analog

GHRPs are frequently studied alongside a GHRH analog such as CJC-1295 (often the non-DAC “mod GRF 1-29” form) or tesamorelin. The two act through different receptors: the GHRH analog amplifies the amount of GH released, while the GHRP triggers and sharpens the pulse. Combined, they tend to produce a larger, more physiological GH pulse than either alone, which is why the pairing is so common in the literature.

Reported side effects and open questions (research context)

These are not approved medicines, so there is no clinical regimen, and this guide does not give amounts, timing or schedules. Effects commonly noted in research reports include water retention, tingling, a transient head-rush, and, for GHRP-6, hunger. Food, especially fats and carbohydrates, blunts the growth hormone response to GHRPs, which matters when interpreting study results.

How to Buy GHRP-2 and GHRP-6 Safely

As with any research peptide, source on documentation: a batch-specific COA that matches the lot number on the vial and can be verified, showing HPLC purity and identity confirmation, plus cold-chain shipping. PrymaLab tests every lot in its own laboratory (RP-HPLC purity, LC-MS identity), its certificates can be checked at prymalab.net/testing/verify, and its third-party testing guarantee refunds the order and reimburses the test if any independent laboratory finds the wrong compound or less than the stated purity or amount. Browse PrymaLab's growth hormone & performance peptides.

Frequently Asked Questions

What is the main difference between GHRP-2 and GHRP-6?

Both are ghrelin-mimicking growth hormone releasing peptides, but GHRP-2 is the more potent GH releaser with comparatively mild appetite stimulation, while GHRP-6 causes pronounced hunger alongside its GH pulse. In research, GHRP-2 is favored when appetite is unwanted and GHRP-6 when increased intake is part of the design.

How do GHRP-2 and GHRP-6 differ from synthetic HGH?

GHRPs work upstream: they prompt the pituitary to release the body's own growth hormone in natural pulses and preserve feedback regulation. Synthetic HGH supplies the hormone directly from outside, overriding those feedback loops. GHRPs are research compounds; HGH is a prescription drug.

Why are GHRPs studied with CJC-1295 (without DAC)?

GHRPs and the GHRH analog CJC-1295 act through different receptors, so combining them produces a larger, more physiological GH pulse than either alone. The GHRH analog increases the amount of GH released while the GHRP triggers the pulse. The pairing is common throughout the research literature.

Does GHRP-6 always cause hunger?

GHRP-6's appetite reputation rests on its ghrelin-like signaling: the finding that ghrelin stimulates food intake comes from rats (Wren et al. 2000), and no GHRP-6 feeding study is cited in this guide. GHRP-2 is reported to stimulate appetite less.

Why does food matter in GHRP studies?

Food, especially fats and carbohydrates, blunts the growth hormone response to GHRPs, so studies typically measure that response in the fasted state.

What side effects are reported with GHRP-2 and GHRP-6?

Commonly noted effects include water retention, tingling, a transient head-rush or flushing, and — especially with GHRP-6 — strong hunger. Higher doses can modestly raise cortisol and prolactin. Because there is limited human trial data, the full profile is not established; these are research compounds only.

How do I buy GHRP-2 or GHRP-6 safely?

Check that the batch-specific Certificate of Analysis matches the lot number on the vial and can be verified, and that it shows HPLC purity and identity confirmation; buy from suppliers that ship lyophilized vials cold. Avoid offshore listings with missing COAs or extreme discounts. These remain research-use-only compounds.

Related reading

• MK-677 (ibutamoren): mechanism, trials and side effects
• CJC-1295: DAC modification and half-life explained

References & Further Reading